| Lymphoid Neoplasm altered in cohorts of …ALTERED_INderived200 of 295show all (up to 200) |
|---|
| ← altered in cohorts of | IGHV2-70 437 / 961 cases (45 %) · ssm · MMRF-COMMPASS · largest of 2 cohorts | — | — | Multiple Myeloma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | DDX3X 124 / 297 cases (42 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | IGLV3-1 364 / 961 cases (38 %) · ssm · MMRF-COMMPASS · largest of 2 cohorts | — | — | Multiple Myeloma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | RHOA 40 / 131 cases (31 %) · ssm · mtnn_msk_2022 | — | — | T-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | SHCBP1 73 / 263 cases (28 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VPS35 67 / 263 cases (25 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ORC6 66 / 263 cases (25 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TPTE 66 / 263 cases (25 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IGHV2-70D 238 / 961 cases (25 %) · ssm · MMRF-COMMPASS · largest of 2 cohorts | — | — | Multiple Myeloma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | KMT2D 247 / 1,001 cases (25 %) · ssm · dlbcl_duke_2017 · largest of 6 cohorts | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 6 | Observed | cbioportal | graph → |
| ← altered in cohorts of | KRAS 227 / 961 cases (24 %) · ssm · MMRF-COMMPASS · largest of 3 cohorts | — | — | Multiple Myeloma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | MYLK3 62 / 263 cases (24 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CNTNAP3B 70 / 297 cases (24 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | BCL7A 212 / 961 cases (22 %) · ssm · MMRF-COMMPASS · largest of 3 cohorts | — | — | Multiple Myeloma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | IGLL5 211 / 961 cases (22 %) · ssm · MMRF-COMMPASS · largest of 4 cohorts | — | — | Multiple Myeloma | 4 | Observed | gdc | graph → |
| ← altered in cohorts of | C16orf87 56 / 263 cases (21 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LTB 186 / 961 cases (19 %) · ssm · MMRF-COMMPASS · largest of 2 cohorts | — | — | Multiple Myeloma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | NRAS 183 / 961 cases (19 %) · ssm · MMRF-COMMPASS · largest of 3 cohorts | — | — | Multiple Myeloma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | PTPRC 50 / 263 cases (19 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DNMT3A 25 / 132 cases (19 %) · ssm · mtnn_msk_2022 | — | — | T-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | GARIN4 55 / 297 cases (19 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ZNF280B 48 / 263 cases (18 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF280A 47 / 263 cases (18 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FBXO11 53 / 297 cases (18 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | GGTLC2 46 / 263 cases (17 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAME 46 / 263 cases (17 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MYD88 172 / 1,001 cases (17 %) · ssm · dlbcl_duke_2017 · largest of 5 cohorts | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 5 | Observed | cbioportal | graph → |
| ← altered in cohorts of | BTG1 67 / 396 cases (17 %) · ssm · mbn_msk_2024 · largest of 2 cohorts | — | — | B-Cell Non-Hodgkin Lymphoma | 2 | Observed | cbioportal | graph → |
| ← altered in cohorts of | OR11H12 44 / 263 cases (17 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GP6 49 / 297 cases (16 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ATP6V1G3 43 / 263 cases (16 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLAMF6 43 / 263 cases (16 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NEB 123 / 755 cases (16 %) · ssm · mbn_mdacc_2013 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | SF3B1 174 / 1,075 cases (16 %) · ssm · cll_broad_2022 · largest of 4 cohorts | — | — | Small Lymphocytic Lymphoma | 4 | Observed | cbioportal | graph → |
| ← altered in cohorts of | AKAP10 47 / 297 cases (16 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | MAP3K9 47 / 297 cases (16 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | CD84 40 / 263 cases (15 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ENSA 40 / 263 cases (15 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MIR5195 143 / 961 cases (15 %) · ssm · MMRF-COMMPASS | — | — | Multiple Myeloma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ADAMTSL4 39 / 263 cases (15 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf56 39 / 263 cases (15 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CD48 39 / 263 cases (15 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CDC42SE1 39 / 263 cases (15 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GABPB2 39 / 263 cases (15 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GOLPH3L 39 / 263 cases (15 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MLLT11 39 / 263 cases (15 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TARS2 39 / 263 cases (15 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PIM1 147 / 1,001 cases (15 %) · ssm · dlbcl_duke_2017 · largest of 5 cohorts | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 5 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ANXA9 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARNT 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BNIPL 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CTSK 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CTSS 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CTXND2 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ECM1 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM243B 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HORMAD1 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNE1B 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MCL1 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MINDY1 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRUNE1 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLAMF1 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLAMF7 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SMIM11B 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SMIM34B 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FRG2C 42 / 297 cases (14 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | SMPD1 42 / 297 cases (14 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | SPATA31A6 42 / 297 cases (14 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ZNF701 42 / 297 cases (14 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | CERS2 37 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GPT2 37 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LYSMD1 37 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPRD2 37 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SCNM1 37 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SEMA6C 37 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SETDB1 37 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMOD4 37 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TNFAIP8L2 37 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VANGL2 37 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VPS72 37 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HLA-A 55 / 396 cases (14 %) · ssm · mbn_msk_2024 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | L1TD1 41 / 297 cases (14 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | FCRL4 36 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NEK7 36 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PIP5K1A 36 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRPF3 36 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CD79B 54 / 396 cases (14 %) · ssm · mbn_msk_2024 · largest of 3 cohorts | — | — | B-Cell Non-Hodgkin Lymphoma | 3 | Observed | cbioportal | graph → |
| ← altered in cohorts of | APH1A 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf54 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CA14 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CIART 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCRL1 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCRL2 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCRL3 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCRL5 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MRPS21 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NCSTN 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NHLH1 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SERPINC1 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SYT11 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GPR52 34 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RABGAP1L 34 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RC3H1 34 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC4B 38 / 297 cases (13 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ANP32E 33 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CD5L 33 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | COPA 33 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DARS2 33 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GON4L 33 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PGM5 33 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PSMD4 33 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZBTB37 33 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | APOA2 32 / 263 cases (12 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DAP3 32 / 263 cases (12 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DCAF8 32 / 263 cases (12 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DNAJA2 32 / 263 cases (12 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCER1G 32 / 263 cases (12 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LY9 32 / 263 cases (12 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MSTO1 32 / 263 cases (12 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NR1I3 32 / 263 cases (12 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PEX19 32 / 263 cases (12 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RCSD1 32 / 263 cases (12 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMEM252 32 / 263 cases (12 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TOMM40L 32 / 263 cases (12 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | YY1AP1 32 / 263 cases (12 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF687 32 / 263 cases (12 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IGHV1-69D 115 / 961 cases (12 %) · ssm · MMRF-COMMPASS | — | — | Multiple Myeloma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TENT5C 115 / 961 cases (12 %) · ssm · MMRF-COMMPASS | — | — | Multiple Myeloma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CD244 31 / 263 cases (12 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ITLN1 31 / 263 cases (12 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | USP21 31 / 263 cases (12 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLFNL1 35 / 297 cases (12 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | CREBBP 115 / 1,001 cases (11 %) · ssm · dlbcl_duke_2017 · largest of 4 cohorts | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 4 | Observed | cbioportal | graph → |
| ← altered in cohorts of | SULT6B1 34 / 297 cases (11 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | IL12RB1 33 / 297 cases (11 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | MYC 82 / 755 cases (11 %) · ssm · mbn_mdacc_2013 · largest of 4 cohorts | — | — | B-Cell Non-Hodgkin Lymphoma | 4 | Observed | cbioportal | graph → |
| ← altered in cohorts of | KIAA1671 32 / 297 cases (11 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | KIR3DL2 32 / 297 cases (11 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | PCBP1 32 / 297 cases (11 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | MUC16 102 / 961 cases (11 %) · ssm · MMRF-COMMPASS · largest of 2 cohorts | — | — | Multiple Myeloma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | H1-4 105 / 1,001 cases (10 %) · ssm · dlbcl_duke_2017 · largest of 4 cohorts | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 4 | Observed | cbioportal | graph → |
| ← altered in cohorts of | BMP6 100 / 961 cases (10 %) · ssm · MMRF-COMMPASS | — | — | Multiple Myeloma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TNFAIP3 41 / 396 cases (10 %) · ssm · mbn_msk_2024 · largest of 2 cohorts | — | — | B-Cell Non-Hodgkin Lymphoma | 2 | Observed | cbioportal | graph → |
| ← altered in cohorts of | HERC2 78 / 755 cases (10 %) · ssm · mbn_mdacc_2013 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ATM 111 / 1,075 cases (10 %) · ssm · cll_broad_2022 · largest of 5 cohorts | — | — | Small Lymphocytic Lymphoma | 5 | Observed | cbioportal | graph → |
| ← altered in cohorts of | IGKV4-1 99 / 961 cases (10 %) · ssm · MMRF-COMMPASS | — | — | Multiple Myeloma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAS 40 / 396 cases (10 %) · ssm · mbn_msk_2024 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | OR10R2 30 / 297 cases (10 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | DIS3 97 / 961 cases (10 %) · ssm · MMRF-COMMPASS | — | — | Multiple Myeloma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMSB4X 97 / 961 cases (10 %) · ssm · MMRF-COMMPASS | — | — | Multiple Myeloma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BCL2 101 / 1,001 cases (10 %) · ssm · dlbcl_duke_2017 · largest of 4 cohorts | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 4 | Observed | cbioportal | graph → |
| ← altered in cohorts of | SPEN 101 / 1,001 cases (10 %) · ssm · dlbcl_duke_2017 · largest of 2 cohorts | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 2 | Observed | cbioportal | graph → |
| ← altered in cohorts of | CD58 39 / 396 cases (9.8 %) · ssm · mbn_msk_2024 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | IRF4 39 / 396 cases (9.8 %) · ssm · mbn_msk_2024 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | IGHV4-34 29 / 297 cases (9.8 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ARID1A 96 / 1,001 cases (9.6 %) · ssm · dlbcl_duke_2017 · largest of 4 cohorts | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 4 | Observed | cbioportal | graph → |
| ← altered in cohorts of | LILRA6 28 / 297 cases (9.4 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | MAGEC1 28 / 297 cases (9.4 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | SIN3A 28 / 297 cases (9.4 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | SOCS1 92 / 1,001 cases (9.2 %) · ssm · dlbcl_duke_2017 · largest of 4 cohorts | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 4 | Observed | cbioportal | graph → |
| ← altered in cohorts of | GNAI2 27 / 297 cases (9.1 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | H1-2 36 / 396 cases (9.1 %) · ssm · mbn_msk_2024 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | KIR3DL1 27 / 297 cases (9.1 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | TCF3 27 / 297 cases (9.1 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | TRAF3 86 / 961 cases (8.9 %) · ssm · MMRF-COMMPASS | — | — | Multiple Myeloma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CARD11 89 / 1,001 cases (8.9 %) · ssm · dlbcl_duke_2017 · largest of 3 cohorts | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 3 | Observed | cbioportal | graph → |
| ← altered in cohorts of | MUC4 26 / 297 cases (8.8 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | MUC5AC 26 / 297 cases (8.8 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | PRIM2 26 / 297 cases (8.8 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | CSMD3 84 / 961 cases (8.7 %) · ssm · MMRF-COMMPASS · largest of 3 cohorts | — | — | Multiple Myeloma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | FAT4 84 / 961 cases (8.7 %) · ssm · MMRF-COMMPASS · largest of 3 cohorts | — | — | Multiple Myeloma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | FOXO1 34 / 396 cases (8.6 %) · ssm · mbn_msk_2024 · largest of 2 cohorts | — | — | B-Cell Non-Hodgkin Lymphoma | 2 | Observed | cbioportal | graph → |
| ← altered in cohorts of | TP53 91 / 1,075 cases (8.5 %) · ssm · cll_broad_2022 · largest of 8 cohorts | — | — | Small Lymphocytic Lymphoma | 8 | Observed | cbioportal | graph → |
| ← altered in cohorts of | RYR2 81 / 961 cases (8.4 %) · ssm · MMRF-COMMPASS · largest of 3 cohorts | — | — | Multiple Myeloma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | TFAP4 25 / 297 cases (8.4 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | PIEZO1 63 / 755 cases (8.3 %) · ssm · mbn_mdacc_2013 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | PRDM1 33 / 396 cases (8.3 %) · ssm · mbn_msk_2024 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ARID1B 83 / 1,001 cases (8.3 %) · ssm · dlbcl_duke_2017 · largest of 2 cohorts | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 2 | Observed | cbioportal | graph → |
| ← altered in cohorts of | GNA13 83 / 1,001 cases (8.3 %) · ssm · dlbcl_duke_2017 · largest of 4 cohorts | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 4 | Observed | cbioportal | graph → |
| ← altered in cohorts of | SETD1B 83 / 1,001 cases (8.3 %) · ssm · dlbcl_duke_2017 · largest of 2 cohorts | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 2 | Observed | cbioportal | graph → |
| ← altered in cohorts of | PCDH15 79 / 961 cases (8.2 %) · ssm · MMRF-COMMPASS | — | — | Multiple Myeloma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAT3 78 / 961 cases (8.1 %) · ssm · MMRF-COMMPASS · largest of 3 cohorts | — | — | Multiple Myeloma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | H1-5 32 / 396 cases (8.1 %) · ssm · mbn_msk_2024 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | LILRB3 24 / 297 cases (8.1 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | MUC3A 24 / 297 cases (8.1 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | FBXW7 59 / 739 cases (8.0 %) · ssm · bll_target_gdc | — | — | B Lymphoblastic Leukemia/Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | TNFRSF14 79 / 1,001 cases (7.9 %) · ssm · dlbcl_duke_2017 · largest of 3 cohorts | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 3 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ACTG1 31 / 396 cases (7.8 %) · ssm · mbn_msk_2024 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | NRXN1 75 / 961 cases (7.8 %) · ssm · MMRF-COMMPASS | — | — | Multiple Myeloma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IGLV5-45 58 / 755 cases (7.7 %) · ssm · mbn_mdacc_2013 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | LRP1B 73 / 961 cases (7.6 %) · ssm · MMRF-COMMPASS · largest of 3 cohorts | — | — | Multiple Myeloma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | DUSP2 76 / 1,001 cases (7.6 %) · ssm · dlbcl_duke_2017 · largest of 2 cohorts | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 2 | Observed | cbioportal | graph → |
| ← altered in cohorts of | H2AC17 30 / 396 cases (7.6 %) · ssm · mbn_msk_2024 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | MGA 75 / 1,001 cases (7.5 %) · ssm · dlbcl_duke_2017 | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | SMARCA4 75 / 1,001 cases (7.5 %) · ssm · dlbcl_duke_2017 · largest of 4 cohorts | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 4 | Observed | cbioportal | graph → |
| ← altered in cohorts of | CCND3 56 / 755 cases (7.4 %) · ssm · mbn_mdacc_2013 · largest of 3 cohorts | — | — | B-Cell Non-Hodgkin Lymphoma | 3 | Observed | cbioportal | graph → |
| ← altered in cohorts of | BMP7 22 / 297 cases (7.4 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | FLG 22 / 297 cases (7.4 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | PZP 22 / 297 cases (7.4 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | RFX7 22 / 297 cases (7.4 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |